Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01697020
Other study ID # INV298
Secondary ID
Status Completed
Phase Phase 1
First received September 20, 2012
Last updated November 28, 2013
Start date September 2012
Est. completion date November 2012

Study information

Verified date November 2013
Source Nova Laboratories Limited
Contact n/a
Is FDA regulated No
Health authority South Africa: Medicines Control Council
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to determine whether the test product, mercaptopurine oral 100 mg/5 mL suspension, and the reference product, Purinethol® 50 mg tablets are bioequivalent. For this purpose the PK profile of 6-mercaptopurine (6-MP) will be compared after administration of a single dose of each of the two formulations, under fasting conditions. The secondary objective is to assess the safety and tolerability of the test product, mercaptopurine oral 100 mg/5 mL suspension.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date November 2012
Est. primary completion date November 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Healthy male subjects, 18 years to 50 years inclusive at time of last administration of the IMP.

- Body Mass Index (BMI) between 18.5 and 30 kg/m2.

- Body mass not less than 50 kg.

- Medical history, physical examination, standard 12-lead electrocardiogram (ECG) and laboratory investigations: Findings clinically acceptable or within laboratory reference ranges for the relevant laboratory tests, unless the investigator considers the deviation to be irrelevant for the purpose of the study.

- Non-smokers.

Exclusion Criteria:

- Current alcohol use > 21 units of alcohol per week for males.

- Regular exposure to substances of abuse (other than alcohol) within the past year.

- Use of any medication, prescribed or over-the-counter or herbal remedies, within 2 weeks prior to the first administration of IMP except if this will not affect the outcome of the study in the opinion of the investigator.

- Participation in another study with an experimental drug, where the last administration of the previous IMP was within 8 weeks before the first administration of IMP in this study.

- Treatment within the previous 3 months before the first administration of IMP with any drug with a well-defined potential for adversely affecting a major organ or system.

- A major illness during the 3 months before commencement of the screening period.

- Subjects with a deficient, low or intermediate TPMT enzyme activity by means of phenotyping.

- Subjects who participated in previous azathioprine/mercaptopurine studies within six months will be excluded.

- Relevant history or laboratory or clinical findings indicative of acute or chronic disease, likely to influence study outcome.

- Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the first administration of IMP.

- Diagnosis of hypotension or hypertension made during the screening period or current diagnosis of hypertension.

- Resting pulse of > 100 beats per minute or < 45 beats per minute during the screening period, either supine or standing.

- Positive testing for HIV and/or Hepatitis B and/or Hepatitis C.

- Positive urine screen for drugs of abuse.

- Positive urine screen for tobacco use.

- Subjects who plan to procreate within 12 weeks after IMP administration, or not willing to practice reliable forms of contraception during the study and for at least 12 weeks after the last dose of IMP.

- Immunization using a live organism vaccine within 4 weeks prior to the first dosing of IMP.

- Any specific IMP safety concern.

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Mercaptopurine 20mg/ml oral suspension
50mg
Mercaptopurine 50mg tablet
50mg

Locations

Country Name City State
South Africa Parexel International, Bloemfontein Early Phase Clinical Unit Bloemfontein

Sponsors (1)

Lead Sponsor Collaborator
Nova Laboratories Limited

Country where clinical trial is conducted

South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bioequivalence At each treatment period, pharmacokinetic blood samples will be collected through the indwelling venous cannula at the following times: pre-dose and post-dose at 0.17, 0.33, 0.5, 0.75, 1.0, 1.33, 1.67, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0 and 12.0 hours.
The primary outcome measures will be
Maximum observed plasma concentration (Cmax).
AUC time zero to time of the last quantifiable concentration (AUC(0-t))
Area under the plasma concentration versus time data pairs, with extrapolation to infinity (AUC(0-8)).
Within 7 days No
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT05772000 - Clinical Significance of Occult Central Nervous System Localization
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT03114865 - A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Phase 1/Phase 2
Not yet recruiting NCT06308588 - Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT05579132 - A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT02231853 - Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2
Recruiting NCT06195891 - Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome Phase 1
Withdrawn NCT02815059 - Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone Phase 1
Completed NCT00390793 - Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. Phase 2
Recruiting NCT05866887 - Insomnia Prevention in Children With Acute Lymphoblastic Leukemia N/A
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting NCT06350994 - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Not yet recruiting NCT04488237 - Vitamin D and Methotrexate Adverse Effects
Completed NCT02544438 - Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Phase 1/Phase 2